Not for a drug (Bryostatin) that, with a successful readout in August, will be the most significant breakthrough drug in Alzheimer's in 20 years. And potentially the only drug that reverses Alzheimer's.
As far as whether 2-73 will be successful in their trials, it seems like a longshot to me until they have results from a well-controlled trial that definitively shows reversal.
Exactly what is complicated about keeping PKCE levels healthy? I've posted several 100 articles that show what happens when it is at unhealthy healthy levels and all the processes and pathways that cause the damage. Not sure how much clearer that could be
I don't follow your logic on "jump starting". Are you saying that since the drug works for severely damaged patients then that means it won't work for anything else? Every single piece of research shows that to NOT be the case. I think logic would dictate if a drug that works in mice works in humans, then there would be more than an average shot that if it works in mice for ALL stages then it could work in humans in ALL stages. I've explained before that it is PROVEN that synapses can be regrown in animals so that isn't even an argument. Now that we've run trials in hundreds of patients and have seen no stratification issues based on scores (even I had been skeptical of worse patients doing better) there is even clinical proof against that argument.
News 
Market Data 
Discover 
AI
